Gold prices steady ahead of Fed decision; weekly weakness noted
Craig B. Reynolds, a director at Masimo Corp (NASDAQ:MASI), a $9.1 billion medical technology company whose shares have surged nearly 47% over the past six months, recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On March 14, Reynolds sold 2,053 shares of Masimo common stock at a weighted average price of $166.13 per share. The sale, conducted under a prearranged trading plan, totaled approximately $341,067.
Following this transaction, Reynolds holds 16,581 shares of Masimo. The sale was executed in compliance with Rule 10b5-1(c) of the Securities Exchange Act, which allows company insiders to set up a predetermined plan to sell stocks. The actual sale prices ranged from $166.02 to $166.34 per share.
In other recent news, Masimo Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $1.80, well above the forecasted $1.42. The company also exceeded revenue projections, reporting $600.7 million against the anticipated $591.64 million. This strong performance is attributed to a 46% increase in operating profit and significant improvements in operating margins. BTIG analyst Sean Lavin responded to these results by raising the stock price target for Masimo to $206, maintaining a Buy rating, citing the company’s effective cost structure optimization and margin expansion efforts. Masimo has updated its FY25 healthcare operating margin guidance to 27.5-28.0%, reflecting a 400 basis point year-over-year expansion at the midpoint. The company has also raised its adjusted EPS guidance for 2025 to a range of $5.10-$5.40, surpassing the consensus estimate of $4.69. Additionally, Masimo reaffirmed its 2025 healthcare revenue guidance of $1.50 billion to $1.53 billion, projecting an 8-11% year-over-year increase. These developments highlight Masimo’s strategic focus on enhancing its market share and sustaining long-term growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.